Extracorporeal Membrane Oxygenation Devices Pipeline Market Landscape Report 2021: Stage of Development, Segment, Regulatory Path, Estimated Approval Date, Ongoing Clinical Trials - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Extracorporeal Membrane Oxygenation Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

"Extracorporeal Membrane Oxygenation Devices - Medical Devices Pipeline Product Landscape, 2021' provides comprehensive information about the Extracorporeal Membrane Oxygenation Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Patients that have developed the inability to properly oxygenate their blood, due to complications of the lung, heart, or both, are candidates to receive extracorporeal membrane oxygenation (ECMO).

Scope

• Extensive coverage of the Extracorporeal Membrane Oxygenation Devices under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Extracorporeal Membrane Oxygenation Devices and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Extracorporeal Membrane Oxygenation Devices under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Extracorporeal Membrane Oxygenation Devices Overview

3 Products under Development

3.1 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Stage of Development

3.2 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Segment

3.3 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Territory

3.4 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Regulatory Path

3.5 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Estimated Approval Date

3.6 Extracorporeal Membrane Oxygenation Devices - Ongoing Clinical Trials

4 Extracorporeal Membrane Oxygenation Devices - Pipeline Products under Development by Companies

4.1 Extracorporeal Membrane Oxygenation Devices Companies - Pipeline Products by Stage of Development

4.2 Extracorporeal Membrane Oxygenation Devices - Pipeline Products by Stage of Development

5 Extracorporeal Membrane Oxygenation Devices Companies and Product Overview

5.1 Boundless Science LLC Company Overview

5.2 CVD Equipment Corp Company Overview

5.3 Elsius Biomedical Inc Company Overview

5.4 Ension, Inc. Company Overview

5.5 FreeFlow Medical Devices LLC Company Overview

5.6 Haemair Ltd Company Overview

5.7 Hemovent GmbH Company Overview

5.8 Inspira Technologies Oxy Bhn Ltd Company Overview

5.9 Jiangsu STMed Technologies Co Company Overview

5.10 LivaNova PLC Company Overview

5.11 MC3 Inc Company Overview

5.12 MedArray Inc. Company Overview

5.13 Nipro Corp Company Overview

5.14 Pavmed Inc Company Overview

5.15 Qfluidics Inc Company Overview

5.16 Shandong University Company Overview

5.17 The Charles Stark Draper Laboratory Inc Company Overview

5.18 Thoratec LLC Company Overview

5.19 University of California San Francisco Company Overview

5.20 Xenios AG Company Overview

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4z6s9a

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900